Literature DB >> 7929188

Modulation of glycosaminoglycan addition in naturally expressed and recombinant human thrombomodulin.

J H Lin1, K McLean, J Morser, T A Young, R M Wydro, W H Andrews, D R Light.   

Abstract

The two major glycoforms of full-length human thrombomodulin (TM), one with (TM(CS+)) and one without (TM(CS-)) chondroitin sulfate (CS) were analyzed on Western blots of primary and transformed cells and in cells expressing recombinant TM. TM on the surface of Chinese hamster ovary and COS-7 cells is solely TM(CS-). Primary arterial endothelial cells (HAEC and HPAEC) express a greater fraction of TM with CS attached than venous cells (HUVEC). Human lung carcinoma cells (A549) express more TM(CS+) than primary cells and recombinant TM on human melanoma cells (CHL-1) occurs in two very high molecular weight forms of TM(CS+). We explored this variation in TM(CS+) with soluble recombinant TM in several cell lines and analyzed the ambiguous CS addition site in human TM by site-directed mutagenesis. Mutation of Ser474 to Ala blocks CS addition in Chinese hamster ovary and COS-7 cells but not CHL-1 cells which add CS to Ser472 and Ser474. Structure of the O-link domain affects partitioning into TM(CS+) since substituting with the decorin CS addition sequence, substituting all Ser and Thr except Ser474 with Ala, and deleting around the potential beta-turn all increase the ratio of TM(CS+) to TM(CS-). A combination of the decorin substitution and deletion of the remaining O-link domain yields the most TM(CS+).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929188

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Human thrombomodulin knock-in mice reveal differential effects of human thrombomodulin on thrombosis and atherosclerosis.

Authors:  Thomas J Raife; Denis M Dwyre; Jeff W Stevens; Rochelle A Erger; Lorie Leo; Katina M Wilson; Jose A Fernández; Jennifer Wilder; Hyung-Suk Kim; John H Griffin; Nobuyo Maeda; Steven R Lentz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

Review 2.  Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease.

Authors:  Joseph Ramli; Pedro CalderonArtero; Robert C Block; Shaker A Mousa
Journal:  Cardiol J       Date:  2011       Impact factor: 2.737

Review 3.  Thrombomodulin and its role in inflammation.

Authors:  Edward M Conway
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

4.  Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT.

Authors:  M Anna Kowalska; Sriram Krishnaswamy; Lubica Rauova; Li Zhai; Vincent Hayes; Karine Amirikian; Jeffrey D Esko; Daniel W Bougie; Richard H Aster; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

Review 5.  Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.

Authors:  Mallorie Boron; Tiffany Hauzer-Martin; Joseph Keil; Xue-Long Sun
Journal:  TH Open       Date:  2022-07-11

6.  Cellular localization of thrombomodulin in human epithelium and squamous malignancies.

Authors:  D J Lager; E J Callaghan; S F Worth; T J Raife; S R Lentz
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

7.  Molecular basis of thrombomodulin activation of slow thrombin.

Authors:  T E Adams; W Li; J A Huntington
Journal:  J Thromb Haemost       Date:  2009-07-28       Impact factor: 5.824

8.  Plasmodium falciparum-infected erythrocytes adhere both in the intervillous space and on the villous surface of human placenta by binding to the low-sulfated chondroitin sulfate proteoglycan receptor.

Authors:  Arivalagan Muthusamy; Rajeshwara N Achur; Veer P Bhavanandan; Genevieve G Fouda; Diane W Taylor; D Channe Gowda
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

9.  Chondroitin sulfate A is a cell surface receptor for Plasmodium falciparum-infected erythrocytes.

Authors:  S J Rogerson; S C Chaiyaroj; K Ng; J C Reeder; G V Brown
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

10.  Inhibition of binding of malaria-infected erythrocytes by a tetradecasaccharide fraction from chondroitin sulfate A.

Authors:  J G Beeson; W Chai; S J Rogerson; A M Lawson; G V Brown
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.